东方生物(688298) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 reached ¥4,746,225,792.78, representing a year-on-year increase of 112.28%[3] - Net profit attributable to shareholders was ¥2,066,679,758.22, reflecting a growth of 74.20% compared to the same period last year[3] - The net cash flow from operating activities amounted to ¥1,774,121,996.77, an increase of 38.86% year-on-year[3] - Total operating revenue for Q1 2022 reached ¥4,746,225,792.78, a significant increase from ¥2,235,856,344.48 in Q1 2021, representing a growth of approximately 112.5%[14] - Net profit for Q1 2022 was ¥2,098,665,411.07, compared to ¥1,186,088,973.33 in Q1 2021, indicating a year-over-year increase of about 76.8%[16] - In Q1 2022, the total comprehensive income attributable to the parent company was CNY 2,097,145,951.30, compared to CNY 1,188,111,525.52 in Q1 2021, representing an increase of approximately 76.3%[17] Research and Development - Research and development expenses totaled ¥105,097,126.38, marking a significant increase of 351.07% compared to the previous year[3] - Research and development expenses in Q1 2022 amounted to ¥105,097,126.38, up from ¥23,299,512.68 in Q1 2021, reflecting an increase of approximately 351.5%[16] - The company plans to continue expanding its market presence and investing in new technologies, as indicated by the substantial increase in R&D spending[16] Assets and Liabilities - Total assets at the end of the reporting period were ¥11,739,688,381.88, up 30.78% from the end of the previous year[3] - Total assets as of Q1 2022 were ¥11,739,688,381.88, compared to ¥8,976,971,218.27 in Q1 2021, marking a growth of about 30.9%[13] - Total liabilities increased to ¥2,753,753,245.32 in Q1 2022 from ¥2,088,182,033.02 in Q1 2021, representing an increase of approximately 31.8%[13] Cash Flow - The net cash flow from operating activities for Q1 2022 was CNY 1,774,121,996.77, up from CNY 1,277,675,312.02 in Q1 2021, indicating a growth of about 39%[20] - Cash received from sales of goods and services in Q1 2022 was CNY 4,531,483,651.98, significantly higher than CNY 2,183,953,382.26 in Q1 2021, marking an increase of approximately 107.5%[19] - The total cash inflow from operating activities in Q1 2022 was CNY 4,833,667,360.72, compared to CNY 2,263,404,095.16 in Q1 2021, indicating an increase of about 113.4%[20] - The total cash outflow from operating activities in Q1 2022 was CNY 3,059,545,363.95, compared to CNY 985,728,783.14 in Q1 2021, which is an increase of approximately 110.5%[20] - The cash and cash equivalents at the end of Q1 2022 amounted to CNY 7,333,314,003.52, compared to CNY 2,792,086,317.80 at the end of Q1 2021, reflecting an increase of about 162.5%[21] Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,354[8] - The largest shareholder, Anji Fulanglai Import and Export Trade Co., Ltd., holds 19.50% of the shares, followed by Fangs Holdings Limited with 18.75% and Anji Yongwei Investment Partnership with 10.31%, collectively owning 48.56%[9] Inventory and Costs - The company reported a 67.51% increase in inventory due to a significant rise in orders during the reporting period[5] - The company experienced a 213.27% rise in operating costs, correlating with the increase in revenue[5] - The total cost of operations for Q1 2022 was ¥2,213,803,833.87, compared to ¥868,166,045.36 in Q1 2021, reflecting an increase of approximately 154.1%[16] Other Information - The company has not reported any significant changes in shareholder relationships or actions among the top ten shareholders[9] - The company has not disclosed any new product developments or market expansion strategies in the current report[9] - There are no significant reminders or additional important information regarding the company's operational status during the reporting period[10] - The company reported a foreign exchange impact on cash and cash equivalents of -CNY 24,208,528.88 in Q1 2022, compared to a positive impact of CNY 20,798,938.31 in Q1 2021[21]